The STAMPEDE trial: paradigm-changing data through innovative trial design.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

1. Drug Development in Non-Oncogene-Addicted Non-Small Cell Lung Cancer.Cancers · 2026
   Review
2. Has the UK lost its position as a destination for world-leading clinical research? A comparative analysis of haematological cancer clinical trials performance before Brexit.BMJ open · 2024
   Article
3. Impact of cell plasticity on prostate tumor heterogeneity and therapeutic response.American journal of clinical and experimental urology · 2024
   Review
4. Prostate cancer across four countries in the Middle East: a multi-centre, observational, retrospective and prognostic study.Ecancermedicalscience · 2024
   Article
5. Challenges, Complexities, and Considerations in the Design and Interpretation of Late-Phase Oncology Trials.Seminars in radiation oncology · 2023
   Review
6. Improving the efficiency of clinical trials in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023
   Review
7. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.The Prostate · 2020
   Article
8. Epidemiology, Staging and Management of Prostate Cancer.Medical sciences (Basel, Switzerland) · 2020
   Review
9. The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells.PloS one · 2020
   Article
10. The future of clinical trials in urological oncology.Nature reviews. Urology · 2019
    Review
11. Localising occult prostate cancer metastasis with advanced imaging techniques (LOCATE trial): a prospective cohort, observational diagnostic accuracy trial investigating whole-body magnetic resonance imaging in radio-recurrent prostate cancer.BMC medical imaging · 2019
    Observational
12. From separation to collaboration: the future of urology.Nature reviews. Urology · 2019
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 2 institutions in 1 country.

Funding

Abstract

Indexed as